Latvian Institute of Organic Synthesis has identified selenium compounds acting as estrogen receptor α (ER-α; ESR1) modulators reported to be useful for the treatment of cancer.
Nanjing Mingde New Drug Research Co. Ltd. has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding agent coupled to an estrogen receptor α (ER-α; ESR1)-targeting moiety via linker. They are reported to be useful for the treatment of breast cancer.
Icecure Medical Ltd.’s Prosense system demonstrated a 100% success rate in destroying breast cancer tumors that were less than or equal to 25 millimeters, according to a study published in the British Journal of Radiology.
Researchers at Rockefeller University have identified a signaling loop between breast cancer cells and sensory neurons that promoted tumor metastasis, and showed that in animal models, treatment with the approved anti-nausea medication aprepitant could disrupt that loop.
For the first time in six years, the U.K.’s National Institute for Health and Care Excellence (NICE) is refusing to recommend a breast cancer treatment. It cited price as the issue.
Researchers from Northeast Normal University in Changchun demonstrated that compound AW-01178 reversed the abnormal regulation of E-cadherin by inhibiting the class I HDAC enzyme.
The first patenting to be published in the name of Wave View Imaging Inc. sees its co-founders file for additional protection of their imaging technology which can be used to monitor breast cancer treatment.
Researchers from Shuttle Pharmaceuticals LLC and Georgetown University have described the in vitro and in vivo profile of SP-1-303, designed as a dual-function histone deacetylase (HDAC) inhibitor and ataxia-telangiectasia mutated protein (ATM) activator, in breast cancer models.
